**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Nirija Ranjit Anderson, Princess Alexandra Hospital, Brisbane, Queensland, Australia

**Main Body of the Abstract**
Aim:
18F-florbetaben is a novel radiotracer that has previously demonstrated capability in delineating between cardiac amyloidosis and other causes of cardiac hypertrophy. We aim to assess the utility of 18F-florbetaben PET/CT for cardiac imaging in patients with systemic AL amyloidosis.
Method:
Newly diagnosed or previously treated patients with systemic AL amyloidosis and suspected cardiac involvement were prospectively recruited to undergo a 18F-florbetaben PET/CT scan.
Percentage of myocardial tracer retention (MTR) was calculated from mean left ventricular (LV) myocardial standardised uptake values (SUVmean) at 0-5mins and 15-20mins. This was compared to current standard assessments of cardiac amyloidosis (transthoracic echocardiogram, serum cardiac biomarkers) and cardiac staging using modified Mayo 2004 staging.
Results:
17 patients underwent a 18F-florbetaben PET/CT scan. Time activity curves demonstrating myocardial 18F-florbetaben retention over time are demonstrated in figure 1. High 18F-florbetaben uptake in the left ventricular wall was clearly demonstrated via visual assessment in all except 2 patients who had a MTR of ≤ 40%, which has been previously been defined as a cut-off for excluding cardiac amyloidosis. On review, an alternative cause of heart failure or low likelihood of cardiac amyloidosis was determined for these patients.
A correlation was demonstrated between MTR and LV GLS (r=0.5, p=0.026). Participants with advanced cardiac disease (Mayo stage III), demonstrated higher tracer uptake (SUVmean 9.26 vs 5.74) but this was limited by small numbers in this study.
Conclusion:
18F-florbetaben PET/CT is complementary to currently available assessment tools and may add value in determining the presence of cardiac amyloidosis in ambiguous cases.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Nirija Ranjit Anderson, Princess Alexandra Hospital, Brisbane, Queensland, Australia

**Main Body of the Abstract**
**Aim:**
18F-florbetaben is a novel radiotracer that has previously demonstrated capability in delineating between cardiac amyloidosis and other causes of cardiac hypertrophy. We aim to assess the utility of 18F-florbetaben PET/CT for cardiac imaging in patients with systemic AL amyloidosis.
**Method:**
Newly diagnosed or previously treated patients with systemic AL amyloidosis and suspected cardiac involvement were prospectively recruited to undergo a 18F-florbetaben PET/CT scan.
Percentage of myocardial tracer retention (MTR) was calculated from mean left ventricular (LV) myocardial standardised uptake values (SUVmean) at 0-5mins and 15-20mins. This was compared to current standard assessments of cardiac amyloidosis (transthoracic echocardiogram, serum cardiac biomarkers) and cardiac staging using modified Mayo 2004 staging.
**Results:**
17 patients underwent a 18F-florbetaben PET/CT scan. Time activity curves demonstrating myocardial 18F-florbetaben retention over time are demonstrated in figure 1. High 18F-florbetaben uptake in the left ventricular wall was clearly demonstrated via visual assessment in all except 2 patients who had a MTR of ≤ 40%, which has been previously been defined as a cut-off for excluding cardiac amyloidosis. On review, an alternative cause of heart failure or low likelihood of cardiac amyloidosis was determined for these patients.
A correlation was demonstrated between MTR and LV GLS (r=0.5, p=0.026). Participants with advanced cardiac disease (Mayo stage III), demonstrated higher tracer uptake (SUVmean 9.26 vs 5.74) but this was limited by small numbers in this study.
**Conclusion:**
18F-florbetaben PET/CT is complementary to currently available assessment tools and may add value in determining the presence of cardiac amyloidosis in ambiguous cases.



Imaging cardiac amyloidosis using 18F-florbetaben positron electron topography (PET) in systemic light chain (AL) amyloidosis. PB106 (#197)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.